U.S. Markets closed

Keryx Biopharmaceuticals, Inc. (KERX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.46+0.04 (+0.62%)
At close: 4:00PM EDT

6.47 0.01 (0.09%)
After hours: 4:47PM EDT

People also watch
AEZSCLDXARNAACADOREX
  • As of 05/15/2017 17,498,249 20% decline in the short interest.
  • $KERX 880 ims. From StockTwits
  • You have an FDA approved stock, you have all insurance companies approved to fund user. You have a new distribution staff in place. Sit back - this stock has takeover all over it. Go ahead and short it. Will keep buying on dips. Tired of this board writing about the ski falling. Its a biotech a takeover and it will rip your heart out shorts.
  • Shorty trying to scare longs out...shorty, i wouldn't sell under $20's this has take out all over it when next Q sales are $20M plus.......
  • Why are we stuck at 6.40. It seems someone is really trying to keep it at this price for today.
  • 5/15/2017 17,498,249 2,126,582 8.228344
    4/28/2017 21,948,085 853,233 25.723437
    4/13/2017 22,045,076 878,726 25.087543

    Read more: http://www.nasdaq.com/symbol/kerx/short-interest#ixzz4i5quuyEl

    Keryx Biopharmaceuticals, Inc. (KERX) Short Interest
    Keryx Biopharmaceuticals, Inc. (KERX) Short Interest � Find short interest for Keryx Biopharmaceuticals, Inc. and all the companies you research at NASDAQ.com
    www.nasdaq.com
  • Not sure why everyone is happy shorts are getting off the hook....NO short squeeze to get us back to 16 sucks....they took us down and now slithering out scott free.....too bad
  • Auryxia should be the first binder of choice. If a patient has no serious side effects then the benefits are better than any other binder..
  • And salary decrease of 1000 dollars/day until there is news that makes the stock go up
  • short interest down by 4.5 MIL and we are in red. Difficult to understand.
  • Starting today, the board should subtract 5K of stock from GM every day there is NO news.....
  • craz, if SK is somehow involved in a potential pre-designed plan with Kerx in last years while benefitting on short side and also cashing-in on long side at conclusion, then he can take his co-ownership in horse and Red Sox and shove them where they best fit..,
  • Can't spend more time looking for what I just posted about why the stock price might not go up when there is a significant increase in weekly scripts.
    2017 projected revenues is $64.88 million. I believe 2017 is Auryxia's third year on the market. So if large , savvy investors think revenues might be $80 million instead of $65 million, I think they would still regard the drug as a failure, especially because market share is so small, and I don't think they would invest more. 2018 revenues are supposed to be $129 million. Still not good revenues..
  • $KERX IMS 921.From StockTwits
  • From good old Doug and his parrot

    $KERX Auryxia. Symphony-based TRx increased 9% and IMS-based TRx increased 7% wk/wk (704 vs. 646 and 921 vs. 862).
  • Seth co-owns Cloud Computing the horse that won the Preakness Saturday........Klaravich Stables.....He also is a minority owner of the Red Sox which I didn't know.......
  • Peter J. Enos, PharmDFollow
    Clinical Consultant | www.drpeterjenos.com | info@drpeterjenos.com
    May 16

    Ferric Citrate (AURYXIA®) Drug Monograph
    A Comprehensive Clinical Overview of Auryxia® in a Clinical Monograph

    How Supplied¹
    Tablets — Auryxia 210 mg ferric iron tablets equivalent to 1 g ferric citrate are supplied as 200 tablets in 400 cc high-density polyethylene bottles. The 210 mg ferric iron tablets are film coated, peach colored, and oval-shaped tablet embossed with “KX52”.
    Indications¹
    Control of serum phosphorus levels in patients with chronic kidney disease on dialysis.
    Pharmacology¹²
    Healthy kidneys excrete phosphate extremely efficiently, but in CKD patients, phosphate excretion becomes unpredictable
    As CKD progresses, PTH compensation fails in preventing phosphate reabsorption leading to supra-physiological levels of phosphate from reabsorption
    Upon oral administration, ferric citrate dissociates into ferric iron and citrate
    Ferric iron binds to several dietary phosphate ions in the GI tract and precipitates as ferric phosphate, which is excreted in the stool
    Auryxia ultimately reduces serum phosphate levels by preventing reabsorption
    Pharmacokinetics

    Clinical Efficacy
    US Trials in Dialysis Dependent CKD²
    Dose-response and Efficacy of Ferric Citrate to Treat Hyperphosphatemia in Hemodialysis Patients¹²³
    The study was a phase 3, multicenter, randomized, open-labeled trial comparing three fixed dosed regimens of ferric citrate. The goal of the study was to compare the clinical effectiveness of the three doses of 1g, 6 g, and 8 g ferric citrate. The results of the study concluded that ferric citrate is an effective dietary phosphate binder which reduces phosphorous levels in patients on dialysis.
    Ferric Citrate Controls Phosphorous and Delivers Iron in Patients on Dialysis²⁴
    This study details the findings of a sequential three-period, 58-week, phase 3 randomized controlled trial. The goal of the study was to assess the safety and efficacy of ferric citrate as a phosphate binder in 441 patients with ESRD requiring dialysis. The conclusion of the study states that ferric citrate is an effective dietary phosphorous binder. It also improves ferritin and TSAT levels in addition to requiring less ESA and IV iron used in patients with CKD on dialysis.
    Japan Trials in Dialysis Dependent CKD Patients²
    A Randomized Trial of JTT-751 versus Sevelamer Hydrochloride in Patients on Hemodialysis²⁵
    This study was a phase 3, multicenter, randomized, active-controlled, open-label, parallel group study. The goal of the study was to directly compare JTT-751 (ferric citrate anhydrate) and sevelamer hydrochloride in HD-dependent CKD patients. The conclusion of the study states that serum phosphate concentrations declined significantly in both groups and that intergroup difference was not significant. The study proved that JTT-751 was non-inferior to sevelamer HCl as a phosphate binder for HD-dependent CKD patients. In addition, the study also concluded that JTT-751 led to higher hemoglobin, hematocrit, serum ferritin, and TSAT than sevelamer.
    Long-term Safety and Efficacy of a Novel Iron-containing Phosphate Binder, JTT-751, in Patients Receiving Hemodialysis²⁶
    This study was an open-label, phase 3, multicenter, dose-titration trial that recruit subjects at 29 centers in Japan. The goal of this study was to assess the safety and efficacy of JTT-751 (ferric citrate anhydrate). The conclusion of the study states that JTT-751 effectively controlled serum phosphate concentrations in patients receiving hemodialysis during a full year of study. Study also found that patients who used of JTT-751 significantly reduced IV iron use and ESA usage throughout the study.
    Taiwan Trials in Hemodialysis Dependent CKD²
    Effect of Oral Ferric Citrate on Serum Phosphorus in Hemodialysis Patients²⁷
    This study was a phase 3, randomized, double blind, placebo-controlled study intended to assess the efficacy of ferric citrate as a phosphate binder in patients with ESRD on hemodialysis. The study concluded that oral ferric citrate was a safe and effective option for lowering serum phosphorous in CKD patients on hemodialysis.
    Contraindications/Warnings/Precautions¹²
    Iron overload syndromes such as hemochromatosis (excessive elevations in iron stores)
    Accidental overdose of iron (leading cause of fatal poisoning in children under 6 years of age)
    Patients with inflammatory bowel disease or active/symptomatic gastrointestinal bleeding were excluded from clinical trials. Safety not established in these patients
    Adverse Effects¹²
    May cause discolored (dark) stools, however, this staining is typical with most medications containing iron
    Diarrhea
    Nausea
    Constipation
    Vomiting
    Drug Interactions¹²
    No empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.
    For oral medications where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, consider separation of the timing of the administration between the two drugs.
    Separation with Auryxia depends on absorption characteristics of the medications administered concomitantly (such as time to reach peak systemic levels or whether the drug is an immediate or extended release product)
    Consider monitoring clinical responses or blood levels of concomitant medications that have a narrow therapeutic range

    Drug/Food/Nutrient Interactions
    N/A
    Dosage Guidelines and Monitoring¹
    Auryxia 210 mg ferric iron, equivalent to 1 g ferric citrate, film coated, peach colored, and oval-shaped tablet embossed with “KX52”.
    Pediatric Dosing: N/A¹
    The safety and efficacy of Auryxia have not been established in pediatric patients
    Administration Options¹²
    Take two 1gram tablet orally 3 times per day with meals
    Maximum dose of 12 tablets daily
    Dose can be titrated at 1-week or longer intervals
    Monitoring parameters¹²
    Monitor serum phosphorous levels
    Titrate in decrements or increments of 1 to 2 tablets per day as needed to maintain target serum phosphorous levels
    Monitor for signs and symptoms of iron overload and accidental iron overdose
    Medication Safety Issues¹
    Pregnancy
    Pregnancy Category B
    No adequate and well-controlled studies in pregnant women
    Overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes, and fetal malformation
    Labor and Delivery
    Effects of Auryxia on labor and delivery are unknown
    Nursing Mothers
    Data from rats have shown transfer of iron into milk by divalent metal transporter-1 (DMT-1) and ferroportin-1 (FPN-1).
    Possibility of infant exposure when Auryxia is administered to a nursing woman
    Geriatric Use
    Clinical study experience has not identified any obvious differences in responses between the elderly and younger patients in the tolerability or efficacy of Auryxia
    Overdose
    No data available regarding overdose of Auryxia
    Maximum dose studied was 12 tablets per day
    May lead to excessive elevations in iron stores (especially with concomitant IV iron use)
    Keep away from children to prevent accidental overdose
    Storage
    Store at 20°C to 25°C (68°F to 77°F)
    Excursions permitted to 15°C to 30°C (59°F to 86°F)
    Protect from moisture
    Cost Comparison²

    Conclusion and Recommendations²⁸
    Auryxia is comparable to other non-calcium based phosphate binders in terms of efficacy and price. The major advantage of Auryxia are the studies supporting the reduction in use of IV iron and ESAs. An additional study utilizing Lewis et al. trial projected a cost savings of $2,101 per patient per year with approximately $1,585 of the savings directly related from less use of ESAs. Since CKD is a chronic disease requiring regular use of IV iron and ESAs, we the study states that cost savings could continue for the entire duration of treating a CKD patient
    Auryxia is a safe and effective phosphate binder with limited side effects and limited drug interactions. It has the potential to reduce IV iron use and ESA usage which could potentially impact cost savings.
    References:
    Full Prescribing Information. Auryxia, ferric citrate tablets. Keryx Biopharmaceuticals, Boston, MA, 2016.
    Pennoyer A, Bridgeman MB. Ferric Citrate (Auryxia) for the Treatment of Hyperphosphatemia. Pharmacy and Therapeutics. 2015;40(5):329–339.
    Dwyer JP, Sika M, Schulman G, et al. Dose–response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis. 2013;61:759–766.
    Lewis JB, Sika M, Koury MJ, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2014;26:e1–e11.
    Yokoyama K, Akiba T, Fukagawa M, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant. 2014;29:1053–1060.
    Yokoyama K, Akiba T, Fukagawa M, et al. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. J Ren Nutr. 2014;24:261–267.
    Lee CT, Wu IW, Chiang SS, et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study. J Nephrol. 2015;28:105–113.
    Rodby R, Umanath K, Hsieh A, et al. Phosphorus binding with ferric citrate reduces erythropoiesis-stimulating agent (ESA) and IV iron usage and cost in patients with ESRD [abstract] Am J Kidney Dis. 2014;63:B95.

    drpeterjenos
    www.drpeterjenos.com
  • From stocktwits

    May, 19 3.10 pm
    user_1234
    $KERX Shares available short on Fidelity 2,502,683
  • Market loves the new script numbers. Stock up 2 cents!
  • KERX Management hard at work!!!
    Imagethe-dodo